Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy

Fig. 3

SULpeak percentage change between baseline and follow-up for all eight observers (A–H). Note: where agreement is complete all eight observations are stacked. The horizontal lines represent the 30 % change levels used for discrimination between response categories according to PERCIST 1.0. The arrows mark three patient in whom a discrepancy results in different categorization. Red arrow: A misclassification of possible clinical importance where G reported PMD (30.8 % increase in SULpeak) and the other observers reported SMD (28.6 %). The two black arrows: E reports SMD (13.6 % SULpeak change) the others reported PMR (43 % change) and an example where H report SMD (14.4 % decrease in SULpeak) and the other observers report PMR (69.9 % decrease)

Back to article page